검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Cyclin-Dependent Kinase 6 Inhibitor (Cyclin-Dependent Kinase 6 Inhibitor) SWOG Cancer Research Network·HER2 ORR 24% |
|---|---|
Overview Program | Cyclin-Dependent Kinase 6 Inhibitor |
Overview Company | SWOG Cancer Research Network |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | target of rapamycin (mTOR) pathway |
MoA Biomarker | biomarker for high-grade cervical lesion identification |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Anti colorectal cancer activity and in silico studies of novel pyridine nortopsentin analog as cyclin dependent kinase 6 inhibitor.. Nortopsentins are a vital class of deep-sea sponge metabolites which can be used as leads for antitumor agents. Although their action has been studied in several diseases' contexts, their cytotoxic activity against colorectal carcinoma has not yet been fully investig… |
Clinical Primary efficacy | ORR 24% |
Clinical ORR | 24% |
Clinical PFS | 36 |
Clinical OS | 64.6 |
Clinical Result source | ClinicalTrials.gov NCT04887831 |
Clinical Data Tier / Score | A · 57 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Cyclin-Dependent Kinase 6 Inhibitor (Cyclin-Dependent Kinase 6 Inhibitor) SWOG Cancer Research Network·HER2 ORR 24% |
|---|---|
Overview Program | Cyclin-Dependent Kinase 6 Inhibitor |
Overview Company | SWOG Cancer Research Network |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | target of rapamycin (mTOR) pathway |
MoA Biomarker | biomarker for high-grade cervical lesion identification |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Anti colorectal cancer activity and in silico studies of novel pyridine nortopsentin analog as cyclin dependent kinase 6 inhibitor.. Nortopsentins are a vital class of deep-sea sponge metabolites which can be used as leads for antitumor agents. Although their action has been studied in several diseases' contexts, their cytotoxic activity against colorectal carcinoma has not yet been fully investig… |
Clinical Primary efficacy | ORR 24% |
Clinical ORR | 24% |
Clinical PFS | 36 |
Clinical OS | 64.6 |
Clinical Result source | ClinicalTrials.gov NCT04887831 |
Clinical Data Tier / Score | A · 57 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교